Interferon pathway in SLE: one key to unlocking the mystery of the disease
L Rönnblom, D Leonard - Lupus science & medicine, 2019 - lupus.bmj.com
SLE is characterised by an activation of the interferon (IFN) system, which leads to an
increased expression of IFN-regulated genes. The reasons behind the IFN signature in SLE …
increased expression of IFN-regulated genes. The reasons behind the IFN signature in SLE …
Vitamin D and the immune system
C Aranow - Journal of investigative medicine, 2011 - journals.sagepub.com
It is now clear that vitamin D has important roles in addition to its classic effects on calcium
and bone homeostasis. As the vitamin D receptor is expressed on immune cells (B cells, T …
and bone homeostasis. As the vitamin D receptor is expressed on immune cells (B cells, T …
Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis
Objective To assess the efficacy and safety of the type I interferon receptor antibody,
anifrolumab, in patients with active, biopsy-proven, Class III/IV lupus nephritis. Methods This …
anifrolumab, in patients with active, biopsy-proven, Class III/IV lupus nephritis. Methods This …
Structure and degradation of circular RNAs regulate PKR activation in innate immunity
Circular RNAs (circRNAs) produced from back-splicing of exons of pre-mRNAs are widely
expressed, but current understanding of their functions is limited. These RNAs are stable in …
expressed, but current understanding of their functions is limited. These RNAs are stable in …
Nonlesional lupus skin contributes to inflammatory education of myeloid cells and primes for cutaneous inflammation
Cutaneous lupus erythematosus (CLE) is a disfiguring and poorly understood condition
frequently associated with systemic lupus. Previous studies suggest that nonlesional …
frequently associated with systemic lupus. Previous studies suggest that nonlesional …
Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III …
Objectives To characterise the efficacy and safety of anifrolumab in patients with systemic
lupus erythematosus (SLE) according to interferon gene signature (IFNGS), demographic …
lupus erythematosus (SLE) according to interferon gene signature (IFNGS), demographic …
Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study
M Khamashta, JT Merrill, VP Werth, R Furie… - Annals of the …, 2016 - ard.bmj.com
Objectives The efficacy and safety of sifalimumab were assessed in a phase IIb,
randomised, double-blind, placebo-controlled study (NCT01283139) of adults with …
randomised, double-blind, placebo-controlled study (NCT01283139) of adults with …
Type I interferon in the pathogenesis of lupus
MK Crow - The Journal of Immunology, 2014 - journals.aai.org
Investigations of patients with systemic lupus erythematosus have applied insights from
studies of the innate immune response to define IFN-I, with IFN-α as the dominant mediator …
studies of the innate immune response to define IFN-I, with IFN-α as the dominant mediator …
A regulatory feedback between plasmacytoid dendritic cells and regulatory B cells is aberrant in systemic lupus erythematosus
M Menon, PA Blair, DA Isenberg, C Mauri - Immunity, 2016 - cell.com
Signals controlling the generation of regulatory B (Breg) cells remain ill-defined. Here we
report an" auto"-regulatory feedback mechanism between plasmacytoid dendritic cells …
report an" auto"-regulatory feedback mechanism between plasmacytoid dendritic cells …
The BAFF/APRIL system in SLE pathogenesis
Systemic lupus erythematosus (SLE) is characterized by multisystem immune-mediated
injury in the setting of autoimmunity to nuclear antigens. The clinical heterogeneity of SLE …
injury in the setting of autoimmunity to nuclear antigens. The clinical heterogeneity of SLE …